Thomas Powles, MBBS, MRCP, MD, Barts Cancer Centre at St. Bartholomew’s Hospital, and Vadim Koshkin, MD, University of California, San Francisco, break down the quality-adjusted time without cancer symptoms or toxicity (Q-TWiST) analysis conducted on the JAVELIN Bladder 100 study for the estimated net benefit of avelumab plus best supportive care versus best supportive care alone for patients with advanced urothelial carcinoma.